{
  "trial_id": "NCT00319176",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "nulliparous or multiparous women with intrauterine pregnancies",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "twice daily treatment doses of enoxaparin (1 mg/kg \u00b1 20% SC BID)",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "subjects who consent to the study",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "women who are not pregnant",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "women who are receiving enoxaparin at prophylactic doses (i.e., 30 mg twice daily or 40 mg daily)",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities.",
  "_meta": {
    "topic_id": "72",
    "trial_id": "NCT00319176",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}